A postdoctoral position is presently available in the laboratory. The focus of the laboratory is Molecular Neuropharmacology/Neurodegeneration. Oxidative stress, mitochondrial dysfunction, neuroinflammation and impaired proteostasis are believed to be factors contributing to the development of many chronic neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Nrf2 activation has been shown to combat all of these pathologic mechanisms. Previous work in our laboratory indicates that Nrf2 activation, specifically in astrocytes, confers protection to neighboring neurons in vitro and in vivo. The laboratories goal is to understand how cell-specific activation of Nrf2 in the brain can modulate disease progression in mouse models, as well as human iPSC derived neurons and astrocytes carrying familial mutations associated with early onset of disease. Present work in the laboratory is focused on: 1) using TRAP (translating ribosome affinity purification) to determine cell-specific changes in translating RNA using RNAseq paired with proteomics for validiation of protein changes; 2) identifying the mechanisms in astrocytes and neurons responsible for Nrf2-mediated neuroprotection, as well as how Nrf2 overexpressing astrocytes communicate with neurons; 3) the role of Nrf2 in microglial activation; and 4) viral-mediated delivery of Nrf2 into animal and iPSC models of Alzheimer’s and Parkinson’s Disease. Please contact: Jeffrey A. Johnson, PhD, University of Wisconsin, Phone: (608) 262-2893; e-mail:firstname.lastname@example.org
A Ph.D. in neuroscience or related field. Experience with transgenic animals and primary culture systems including iPSC.